Global Radiation Dermatitis Market
Global Radiation Dermatitis Market

Radiation Dermatitis Comprehensive Study by Type (Grade 1, Grade 2, Grade 3, Grade 4), Application (Hospitals, Pharmaceuticals, Clinics, Others), Drug Administration (Oral, Topical, Dressing, Other) Players and Region - Global Market Outlook to 2026

Radiation Dermatitis Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 208 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Radiation Dermatitis Market Overview:
Radiation Dermatitis is one of the side effects of radiotherapy in the treatment of cancer. Radiation Dermatitis occurs in more than 95% of people who undergo radiation dermatitis. It occurs when radiation therapy damages the outer layer of people’s skin. When hospitals or doctors use X-rays, gamma rays to destroy cancer cells; these rays also make tiny breaks in DNA inside tiny cells to stop it from growing and dividing but this also leads to exposure of these rays to normal rays that get damaged. Radiation Dermatitis has different severity with respect to people. Some individuals experience mild redness while others may experience painful and broken skin. The symptoms of Radiation Dermatitis typically arise after a few weeks or days. Which may include redness or pinkiness of skin, skin swelling, peeling skin, blisters, or skin ulcers. As, radiotherapy is one of the most effective and common methods to treat cancer the radiation dermatitis is very common.

Growth Drivers
  • Growing Prevalence of Cancer Disease and Side Effects Related to the Treatment
  • Need of Radiology for The Treatment of Cancer Which Causes Radiation Dermatitis

Market Trends
  • Increasing Demand for Alcohol-Free Moisturizer for Applying on Affected Skin

Roadblocks
  • Lack of Medical Infrastructure in Developing Countries

Opportunities
  • Availability of Medical Infrastructure in Developed Countries
  • Increasing Spendings of People on the Diagosis

Challenges
  • High Cost Associated with Treating Severe Radiation Dermatitis


Competitive Landscape:
With the increasing use of radiotherapy as a treatment for cancer, the demand for radiation dermatitis medication is increasing. The market is fragmented and does not any distinct market leader. There are no major barriers to entry into the market for new entrants but gaining a good reputation could be a challenge. Radiation Dermatitis is good to segment to expand into if some company is already operating in the skincare market.
Some of the key players profiled in the report are 3M Health Care (United States), Charles River Laboratories (United States), Sonoma Pharmaceuticals (United States), ICON PLC. (Ireland), Eurofins Scientific (Luxembourg), Taconic Biosciences (United States), Mölnlycke Health Care AB (Sweden), Smith & Nephew plc (United Kingdom), EVOTEC (United Kingdom), Integra Lifesciences Holdings Corporation (United States) and Intermed S.A. (Greece). Considering Market by Drug Administration, the sub-segment i.e. Oral will boost the Radiation Dermatitis market.

Dec 10, 2020, Sonoma Pharmaceuticals a healthcare leader who also manufactures medication for Radiation Dermatitis and Crown Laboratories, a global skincare company announced that they have entered into a supply agreement for the exclusive rights to sell and market products for the over-the-counter dermatological market in the United States. Both Companies plan to sell a unique variety of formulations to quickly relieve itch and skin irritations.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Radiation Dermatitis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Radiation Dermatitis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Radiation Dermatitis Medication Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Grade 1
  • Grade 2
  • Grade 3
  • Grade 4
By Application
  • Hospitals
  • Pharmaceuticals
  • Clinics
  • Others
By Drug Administration
  • Oral
  • Topical
  • Dressing
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Cancer Disease and Side Effects Related to the Treatment
      • 3.2.2. Need of Radiology for The Treatment of Cancer Which Causes Radiation Dermatitis
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated with Treating Severe Radiation Dermatitis
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand for Alcohol-Free Moisturizer for Applying on Affected Skin
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radiation Dermatitis, by Type, Application, Drug Administration and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Radiation Dermatitis (Value)
      • 5.2.1. Global Radiation Dermatitis by: Type (Value)
        • 5.2.1.1. Grade 1
        • 5.2.1.2. Grade 2
        • 5.2.1.3. Grade 3
        • 5.2.1.4. Grade 4
      • 5.2.2. Global Radiation Dermatitis by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Pharmaceuticals
        • 5.2.2.3. Clinics
        • 5.2.2.4. Others
      • 5.2.3. Global Radiation Dermatitis by: Drug Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Topical
        • 5.2.3.3. Dressing
        • 5.2.3.4. Other
      • 5.2.4. Global Radiation Dermatitis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Radiation Dermatitis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 3M Health Care (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Charles River Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sonoma Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ICON PLC. (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eurofins Scientific (Luxembourg)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Taconic Biosciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mölnlycke Health Care AB (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Smith & Nephew plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. EVOTEC (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Integra Lifesciences Holdings Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Intermed S.A. (Greece)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Radiation Dermatitis Sale, by Type, Application, Drug Administration and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Radiation Dermatitis (Value)
      • 7.2.1. Global Radiation Dermatitis by: Type (Value)
        • 7.2.1.1. Grade 1
        • 7.2.1.2. Grade 2
        • 7.2.1.3. Grade 3
        • 7.2.1.4. Grade 4
      • 7.2.2. Global Radiation Dermatitis by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Pharmaceuticals
        • 7.2.2.3. Clinics
        • 7.2.2.4. Others
      • 7.2.3. Global Radiation Dermatitis by: Drug Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Topical
        • 7.2.3.3. Dressing
        • 7.2.3.4. Other
      • 7.2.4. Global Radiation Dermatitis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radiation Dermatitis: by Type(USD Million)
  • Table 2. Radiation Dermatitis Grade 1 , by Region USD Million (2015-2020)
  • Table 3. Radiation Dermatitis Grade 2 , by Region USD Million (2015-2020)
  • Table 4. Radiation Dermatitis Grade 3 , by Region USD Million (2015-2020)
  • Table 5. Radiation Dermatitis Grade 4 , by Region USD Million (2015-2020)
  • Table 6. Radiation Dermatitis: by Application(USD Million)
  • Table 7. Radiation Dermatitis Hospitals , by Region USD Million (2015-2020)
  • Table 8. Radiation Dermatitis Pharmaceuticals , by Region USD Million (2015-2020)
  • Table 9. Radiation Dermatitis Clinics , by Region USD Million (2015-2020)
  • Table 10. Radiation Dermatitis Others , by Region USD Million (2015-2020)
  • Table 11. Radiation Dermatitis: by Drug Administration(USD Million)
  • Table 12. Radiation Dermatitis Oral , by Region USD Million (2015-2020)
  • Table 13. Radiation Dermatitis Topical , by Region USD Million (2015-2020)
  • Table 14. Radiation Dermatitis Dressing , by Region USD Million (2015-2020)
  • Table 15. Radiation Dermatitis Other , by Region USD Million (2015-2020)
  • Table 16. South America Radiation Dermatitis, by Country USD Million (2015-2020)
  • Table 17. South America Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 18. South America Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 19. South America Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 20. Brazil Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 21. Brazil Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 22. Brazil Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 23. Argentina Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 24. Argentina Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 25. Argentina Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 26. Rest of South America Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 29. Asia Pacific Radiation Dermatitis, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 32. Asia Pacific Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 33. China Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 34. China Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 35. China Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 36. Japan Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 37. Japan Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 38. Japan Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 39. India Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 40. India Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 41. India Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 42. South Korea Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 43. South Korea Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 44. South Korea Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 45. Taiwan Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 46. Taiwan Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 47. Taiwan Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 48. Australia Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 49. Australia Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 50. Australia Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 54. Europe Radiation Dermatitis, by Country USD Million (2015-2020)
  • Table 55. Europe Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 56. Europe Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 57. Europe Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 58. Germany Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 59. Germany Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 60. Germany Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 61. France Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 62. France Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 63. France Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 64. Italy Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 65. Italy Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 66. Italy Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 67. United Kingdom Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 69. United Kingdom Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 70. Netherlands Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 71. Netherlands Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 72. Netherlands Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 73. Rest of Europe Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 75. Rest of Europe Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 76. MEA Radiation Dermatitis, by Country USD Million (2015-2020)
  • Table 77. MEA Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 78. MEA Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 79. MEA Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 80. Middle East Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 81. Middle East Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 82. Middle East Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 83. Africa Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 84. Africa Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 85. Africa Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 86. North America Radiation Dermatitis, by Country USD Million (2015-2020)
  • Table 87. North America Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 88. North America Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 89. North America Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 90. United States Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 91. United States Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 92. United States Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 93. Canada Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 94. Canada Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 95. Canada Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 96. Mexico Radiation Dermatitis, by Type USD Million (2015-2020)
  • Table 97. Mexico Radiation Dermatitis, by Application USD Million (2015-2020)
  • Table 98. Mexico Radiation Dermatitis, by Drug Administration USD Million (2015-2020)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Radiation Dermatitis: by Type(USD Million)
  • Table 111. Radiation Dermatitis Grade 1 , by Region USD Million (2021-2026)
  • Table 112. Radiation Dermatitis Grade 2 , by Region USD Million (2021-2026)
  • Table 113. Radiation Dermatitis Grade 3 , by Region USD Million (2021-2026)
  • Table 114. Radiation Dermatitis Grade 4 , by Region USD Million (2021-2026)
  • Table 115. Radiation Dermatitis: by Application(USD Million)
  • Table 116. Radiation Dermatitis Hospitals , by Region USD Million (2021-2026)
  • Table 117. Radiation Dermatitis Pharmaceuticals , by Region USD Million (2021-2026)
  • Table 118. Radiation Dermatitis Clinics , by Region USD Million (2021-2026)
  • Table 119. Radiation Dermatitis Others , by Region USD Million (2021-2026)
  • Table 120. Radiation Dermatitis: by Drug Administration(USD Million)
  • Table 121. Radiation Dermatitis Oral , by Region USD Million (2021-2026)
  • Table 122. Radiation Dermatitis Topical , by Region USD Million (2021-2026)
  • Table 123. Radiation Dermatitis Dressing , by Region USD Million (2021-2026)
  • Table 124. Radiation Dermatitis Other , by Region USD Million (2021-2026)
  • Table 125. South America Radiation Dermatitis, by Country USD Million (2021-2026)
  • Table 126. South America Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 127. South America Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 128. South America Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 129. Brazil Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 130. Brazil Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 131. Brazil Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 132. Argentina Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 133. Argentina Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 134. Argentina Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 135. Rest of South America Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 136. Rest of South America Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 137. Rest of South America Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 138. Asia Pacific Radiation Dermatitis, by Country USD Million (2021-2026)
  • Table 139. Asia Pacific Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 140. Asia Pacific Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 141. Asia Pacific Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 142. China Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 143. China Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 144. China Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 145. Japan Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 146. Japan Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 147. Japan Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 148. India Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 149. India Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 150. India Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 151. South Korea Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 152. South Korea Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 153. South Korea Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 154. Taiwan Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 155. Taiwan Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 156. Taiwan Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 157. Australia Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 158. Australia Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 159. Australia Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 163. Europe Radiation Dermatitis, by Country USD Million (2021-2026)
  • Table 164. Europe Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 165. Europe Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 166. Europe Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 167. Germany Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 168. Germany Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 169. Germany Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 170. France Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 171. France Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 172. France Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 173. Italy Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 174. Italy Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 175. Italy Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 176. United Kingdom Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 177. United Kingdom Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 178. United Kingdom Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 179. Netherlands Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 180. Netherlands Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 181. Netherlands Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 182. Rest of Europe Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 183. Rest of Europe Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 184. Rest of Europe Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 185. MEA Radiation Dermatitis, by Country USD Million (2021-2026)
  • Table 186. MEA Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 187. MEA Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 188. MEA Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 189. Middle East Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 190. Middle East Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 191. Middle East Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 192. Africa Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 193. Africa Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 194. Africa Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 195. North America Radiation Dermatitis, by Country USD Million (2021-2026)
  • Table 196. North America Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 197. North America Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 198. North America Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 199. United States Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 200. United States Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 201. United States Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 202. Canada Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 203. Canada Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 204. Canada Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 205. Mexico Radiation Dermatitis, by Type USD Million (2021-2026)
  • Table 206. Mexico Radiation Dermatitis, by Application USD Million (2021-2026)
  • Table 207. Mexico Radiation Dermatitis, by Drug Administration USD Million (2021-2026)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radiation Dermatitis: by Type USD Million (2015-2020)
  • Figure 5. Global Radiation Dermatitis: by Application USD Million (2015-2020)
  • Figure 6. Global Radiation Dermatitis: by Drug Administration USD Million (2015-2020)
  • Figure 7. South America Radiation Dermatitis Share (%), by Country
  • Figure 8. Asia Pacific Radiation Dermatitis Share (%), by Country
  • Figure 9. Europe Radiation Dermatitis Share (%), by Country
  • Figure 10. MEA Radiation Dermatitis Share (%), by Country
  • Figure 11. North America Radiation Dermatitis Share (%), by Country
  • Figure 12. Global Radiation Dermatitis share by Players 2020 (%)
  • Figure 13. Global Radiation Dermatitis share by Players (Top 3) 2020(%)
  • Figure 14. Global Radiation Dermatitis share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. 3M Health Care (United States) Revenue, Net Income and Gross profit
  • Figure 17. 3M Health Care (United States) Revenue: by Geography 2020
  • Figure 18. Charles River Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Charles River Laboratories (United States) Revenue: by Geography 2020
  • Figure 20. Sonoma Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 21. Sonoma Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 22. ICON PLC. (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. ICON PLC. (Ireland) Revenue: by Geography 2020
  • Figure 24. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 25. Eurofins Scientific (Luxembourg) Revenue: by Geography 2020
  • Figure 26. Taconic Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 27. Taconic Biosciences (United States) Revenue: by Geography 2020
  • Figure 28. Mölnlycke Health Care AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 29. Mölnlycke Health Care AB (Sweden) Revenue: by Geography 2020
  • Figure 30. Smith & Nephew plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Smith & Nephew plc (United Kingdom) Revenue: by Geography 2020
  • Figure 32. EVOTEC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. EVOTEC (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Integra Lifesciences Holdings Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 35. Integra Lifesciences Holdings Corporation (United States) Revenue: by Geography 2020
  • Figure 36. Intermed S.A. (Greece) Revenue, Net Income and Gross profit
  • Figure 37. Intermed S.A. (Greece) Revenue: by Geography 2020
  • Figure 38. Global Radiation Dermatitis: by Type USD Million (2021-2026)
  • Figure 39. Global Radiation Dermatitis: by Application USD Million (2021-2026)
  • Figure 40. Global Radiation Dermatitis: by Drug Administration USD Million (2021-2026)
  • Figure 41. South America Radiation Dermatitis Share (%), by Country
  • Figure 42. Asia Pacific Radiation Dermatitis Share (%), by Country
  • Figure 43. Europe Radiation Dermatitis Share (%), by Country
  • Figure 44. MEA Radiation Dermatitis Share (%), by Country
  • Figure 45. North America Radiation Dermatitis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • 3M Health Care (United States)
  • Charles River Laboratories (United States)
  • Sonoma Pharmaceuticals (United States)
  • ICON PLC. (Ireland)
  • Eurofins Scientific (Luxembourg)
  • Taconic Biosciences (United States)
  • Mölnlycke Health Care AB (Sweden)
  • Smith & Nephew plc (United Kingdom)
  • EVOTEC (United Kingdom)
  • Integra Lifesciences Holdings Corporation (United States)
  • Intermed S.A. (Greece)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation